Clinical

Researchers describe the case of an older patient who underwent myeloma drug sensitivity testing as part of an effort to identify the therapies most likely to produce a response in this difficult-to-treat population.

According to new research, 88% of trials initially matched to patients were eventually classified as false positives when manually screened by a provider.

A retrospective study looking at pediatric patients hospitalized in 4 New York hospitals in 2020 with COVID-19 or multisystem inflammatory syndrome in children (MIS-C) found that acute kidney injury (AKI) occurred in 11.8% of patients.

The FDA approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

Despite the level of disease severity of atopic dermatitis, children with the condition usually have at least 1 other inflammatory or atopic comorbidity, according to new study results.

A study finds rates of pediatric COVID-19 cases in Mississippi were largely underestimated; countries with more overweight citizens report more COVID-19 deaths; Senate acts to pass $1.9 trillion relief package.

Targeting pulmonary arterial capacitance or compliance can improve overall survival and quality of life in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension secondary to left heart disease (PH-LHD).

Findings suggest that including slowly repeated evoked pain (SREP) in quantitative sensory testing protocols may enhance assessments of altered pain modulation in different pain conditions.

Triple oral combination therapy with macitentan, riociguat, and selexipag may be a promising strategy to treat patients with low/intermediate-risk pulmonary arterial hypertension (PAH), and possibly even patients with high-risk PAH.

The disorder known as molybdenum cofactor deficiency (MoCD) Type A presents shortly after birth, often with severe encephalopathy and intractable seizures.

More than 2 years after treatment, some of the patients with relapsed/refractory multiple myeloma have yet to see a relapse. An FDA decision on the therapy is expected within a month.

Updates on Waldenström macroglobulinemia treatment formed by an international consensus panel were recently finalized and published in The Lancet Haematology.

While diagnostic algorithms have evolved in the last decade, there remains an urgent need for innovative therapeutic options to treat systemic sclerosis with pulmonary arterial hypertension.

The peptide-drug conjugate rapidly delivers an alkylating payload into tumor cells.

The novel systemic-immune inflammation index (SII) can be used to predict the onset of psoriasis.

Nanotherapies have the potential to overcome the blood-brain barrier and the blood-cerebrospinal fluid barrier, representing a possible treatment opportunity for rare diseases.

The results also showed that the infants achieved certain milestones in motor development, pulmonary function, and survival.

While only 3 small interfering RNA (siRNA)-based therapies have been approved, the market is poised to expand with 7 other candidates in phase 3 trials.

Break Through Cancer, a collaborative research effort between 5 top US academic cancer centers, aims to pursue solutions to some of the most difficult challenges in cancer research.

Genetically decreased vitamin D levels are unlikely to have a large effect on risk of type 1 diabetes, according to results of a Mendelian randomization study published in PLOS Medicine.

Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), a new meta-analysis shows amiselimod had the highest efficacy.

The FDA has granted priority review of the supplemental New Drug Application for ruxolitinib for the treatment of steroid-refractory chronic graft-versus host disease (GVHD).

Elderly patients who recently had a heart attack and fit the criteria for obstructive sleep apnea were shown to be at greater risk for heart rhythm disorders, such as arrhythmia and coronary artery disease, as well as for major adverse cardiovascular and cerebrovascular events.

Health-related quality of life was maintained when treating relapsed/refractory multiple myeloma (RRMM) with daratumumab in combination with bortezomib and dexamethasone.

Advocates for patients with progressive multiple sclerosis (MS) want changes in study designs on emerging therapies to speed development and better align with the needs of researchers and patients.